Organon & Co. (NYSE:OGN) Shares Acquired by Thompson Siegel & Walmsley LLC

Thompson Siegel & Walmsley LLC boosted its holdings in Organon & Co. (NYSE:OGN) by 6.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,262,379 shares of the company’s stock after purchasing an additional 136,457 shares during the quarter. Thompson Siegel & Walmsley LLC’s holdings in Organon & Co. were worth $43,279,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the business. Friedenthal Financial acquired a new position in shares of Organon & Co. during the 2nd quarter valued at about $769,000. Vanguard Group Inc. increased its position in Organon & Co. by 0.6% during the first quarter. Vanguard Group Inc. now owns 30,789,850 shares of the company’s stock worth $578,849,000 after purchasing an additional 192,613 shares during the last quarter. Public Sector Pension Investment Board boosted its holdings in shares of Organon & Co. by 8.0% in the 2nd quarter. Public Sector Pension Investment Board now owns 565,866 shares of the company’s stock valued at $11,713,000 after purchasing an additional 41,954 shares during the last quarter. Beddow Capital Management Inc. grew its stake in shares of Organon & Co. by 38.8% during the 3rd quarter. Beddow Capital Management Inc. now owns 306,675 shares of the company’s stock valued at $5,867,000 after buying an additional 85,775 shares during the period. Finally, O Shaughnessy Asset Management LLC increased its holdings in shares of Organon & Co. by 187.1% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 39,758 shares of the company’s stock worth $747,000 after buying an additional 25,909 shares during the last quarter. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. JPMorgan Chase & Co. downgraded Organon & Co. from a “neutral” rating to an “underweight” rating and boosted their price target for the company from $18.00 to $20.00 in a research report on Friday, September 6th. Evercore ISI upgraded shares of Organon & Co. to a “strong-buy” rating in a report on Wednesday, September 18th.

Organon & Co. Price Performance

OGN stock opened at $14.73 on Thursday. The stock has a 50-day simple moving average of $17.82 and a 200-day simple moving average of $19.85. The firm has a market cap of $3.79 billion, a P/E ratio of 2.92, a price-to-earnings-growth ratio of 0.68 and a beta of 0.84. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a 1 year low of $10.84 and a 1 year high of $23.10.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). The firm had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The company’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.78 EPS. On average, equities analysts predict that Organon & Co. will post 3.89 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Tuesday, November 12th will be given a $0.28 dividend. The ex-dividend date is Tuesday, November 12th. This represents a $1.12 dividend on an annualized basis and a yield of 7.61%. Organon & Co.’s payout ratio is currently 22.22%.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.